Современные аспекты применения позитронно-эмиссионной томографии при лимфомах

The objective was to determine areas of effective application of positron emission tomography (PET) with fluorodeoxyglucose labeled with 18-fluorine ( 18F-FDG) in patients with lymphomas. 18F-FDG PET has become an essential part of a diagnostic algorithm for patients with lymphomas which are characterized by active accumulation of 18F-FDG. High precision of PET in patients with some types of lymphomas permit to use this method effectively in clinical practice for staging of the disease, assessment of the treatment efficacy, more precise diagnosis of the relapse prevalence, assessment of results of the anti-relapse therapy, as well as in case of suspected lymphoma transformation. The use of PET at other stages of treatment of lymphoma patients is still pending further scientific research. In case of indolent lymphomas with known low glycolytic activity or lymphomas of rare histological types, PET is used for assessment of the treatment efficacy only if baseline study results (before initiation of treatment) are available. The Deauville five-score scale criteria should be used for assessment of the treatment efficacy. Timely examination during antitumor treatment permits to increase the precision of the PET diagnosing significantly. Solitary foci found by PET are crucial for the choice of treatment and they should be verified by other diagnostic techniques. It is considered unreasonable to use PET for follow-up observation over patients in remission. PET is a gold standard for staging and assessing the treatment efficacy of lymphomas characterized by active accumulation of 18F-FDG.